Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Preferred Stock Liabilities: 2014

  • CytomX Therapeutics' Preferred Stock Liabilities was N/A to $76.7 million in Q4 2014 from the same period last year, while for Dec 2014 it was $76.7 million, marking a year-over-year change of. This contributed to the annual value of $76.7 million for FY2014, which is N/A change from last year.
  • CytomX Therapeutics' Preferred Stock Liabilities amounted to $76.7 million in Q4 2014.
  • CytomX Therapeutics' 5-year Preferred Stock Liabilities high stood at $76.7 million for Q4 2014, and its period low was $76.7 million during Q4 2014.
  • Moreover, its 1-year median value for Preferred Stock Liabilities was $76.7 million (2014), whereas its average is $76.7 million.